Loading
A phase 2 trial of Pirtobrutinib in non-hodgkin lymphoma, run by Eli Lilly and Company, active and no longer recruiting.
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers is a phase 2 interventional study registered as NCT07162181 by Eli Lilly and Company, with 13 participants planned, started 2025-08-07 and due to reach its primary completion in 2030-05. Interventions recorded: Pirtobrutinib. Conditions listed: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo).
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Shares Eli Lilly (incl. Loxo), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/